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Abstract: Several vaccines with varying efficacies have been developed and are currently adminis-
tered globally to minimize the spread of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Despite having an RNA-dependent RNA polymerase with a proofreading activity, new 
variants of SARS-CoV-2 are on the rise periodically. Some of the mutations in these variants, espe-
cially mutations on the spike protein, aid the virus in transmission, infectivity and host immune 
evasion. Further, these mutations also reduce the effectiveness of some of the current vaccines and 
monoclonal antibodies (mAbs). In the present study, using the available 984,769 SARS-CoV-2 nu-
cleotide sequences on the NCBI database from the end of 2019 till 28 July 2021, we have estimated 
the global prevalence of so-called ‘adaptive mutations’ and ‘mutations identified in the prolonged 
infections’, in the receptor-binding domain (RBD) of the spike (S) protein. Irrespective of the geo-
graphical region, in the case of the adaptive mutations, N501Y (48.38%) was found to be the domi-
nant mutation followed by L452R (17.52%), T478K (14.31%), E484K (4.69%), S477N (3.29%), K417T 
(1.64%), N439K (0.7%) and S494P (0.7%). Other mutations were found to be less prevalent (less than 
0.7%). Since the last two months, there has been a massive increase of L452R and T478K mutations 
(delta variant) in certain areas. In the case of prolonged infections’ mutations (long-term SARS-CoV-
2 infections), V483A (0.009%) was found to be dominant followed by Q493R (0.009%), while other 
mutations were found in less than 0.007% of the studied sequences. The data obtained in this study 
will aid in the development of better infection control policies, thereby curbing the spread of this 
virus. 
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1. Introduction 
Since its discovery in Wuhan, China, at the end of 2019, severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2: COVID-19) has been wreaking havoc globally, both 
in terms of human lives and the economy. SARS-CoV-2 belongs to the Coronaviridae fam-
ily, and the members of this family are enveloped, spherical and carry a single-stranded 
positive-sense RNA (+ssRNA) genome of 27–32 kb [1]. The RNA is capped at the 5′ end, 
and the 3′ end carries a polyA tail [1]. The genomic RNA codes for two polyproteins, 
namely ORF1a and ORF1b (via ribosomal frameshifting), are later cleaved by viral prote-
ases into individual functional non-structural proteins [1,2]. These proteins play a role in 
viral RNA replication and processing [1,2]. The sub-genomic RNA codes for four major 
structural proteins: spike (S), nucleocapsid (N), membrane (M) and envelope (E) [1]. At 
the time of writing this manuscript, globally, 199,374,999 SARS-CoV-2 cases have been 
documented with 4,245,791 deaths (https://www.worldometers.info/coronavirus/, ac-
cessed on 3 August 2021). 
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Coronaviruses are classified into -CoVs, -CoVs and -CoVs [3,4]. SARS-CoV-2 is 
categorized under -CoV. Coronaviruses infect both animals and humans. In humans, 
they can cause both upper and lower respiratory tract infections, and the symptoms can 
range from a mild cold to bronchitis, pneumonia and SARS [5]. Some coronaviruses that 
initially existed in the animal populations (enzootic) can jump into humans and can suc-
cessfully establish diseases in humans [4]. The SARS epidemic between 2002 and 2004 
caused by severe acute respiratory syndrome coronavirus 1 (SARS-CoV or SARS-CoV-1), 
and the periodic Middle East respiratory syndrome (MERS) outbreaks caused by the Mid-
dle East respiratory syndrome-related coronavirus (MERS-CoV) since its discovery in 
2012, are the best examples of coronaviruses that have crossed the animal–human barrier 
[6,7]. It is still not clear how these viruses came into the human population in the first 
place. Some pieces of evidence indicate that these viruses might have jumped from bats 
to humans via an intermediary host [8,9]. On the genome level, SARS-CoV-2 is 86.85% 
identical to SARS-CoV-1 and 81.25% identical to MERS-CoV [10]. 
SARS-CoV-2 spreads mainly via droplets/aerosols from an infected person to a 
healthy person and via fomites. Further, debates are still ongoing regarding the airborne 
transmission of SARS-CoV-2 [11–13]. After inhalation, in the human body, the virus at-
taches to membrane-bound angiotensin-converting enzyme 2 (ACE2) using the S protein, 
and the host serine protease TMPRSS2 primes the S protein for membrane fusion [14]. 
Once inside the cell, like any other virus, SARS-CoV-2 uses the host’s resources for repli-
cation. The pathology is mainly due to the destruction of lung tissues. Currently, there is 
no effective drug against SARS-CoV-2, although remdesivir and other immunosuppres-
sants are prescribed to reduce the severity of the disease [15,16]. 
The S protein of coronaviruses elicits a strong T-cell immune response, and since this 
protein is on the viral surface, especially the S1 subunit, it is a major inducer of virus-
neutralizing antibodies [1]. Unlike SARS-CoV-1 and MERS-CoV, approved vaccines have 
been developed against SARS-CoV-2 and are currently administered to people to reduce 
the spread of this virus. Many of these vaccines use the S protein as a target [17]. Due to 
the infidelity of the viral RNA polymerase, unique random template switching during 
RNA replication and genome plasticity, new variants of SARS-CoV-2 are on the rise [4]. 
Many of these new variants accumulate mutations on the S protein and several of these 
mutations aid the virus in transmission, infectivity and host immune evasion. Further, 
preliminary results suggest that some of these mutations might reduce the effectiveness 
of some of the current vaccines that target the S protein [18,19]. 
In addition to vaccines, monoclonal antibody (mAb) therapy for treating SARS-CoV-
2 infections has shown promise recently [20]. In addition to use as a treatment, mAbs can 
also be used as prophylaxis [20,21]. Recently, several neutralizing mAbs have been devel-
oped against SARS-CoV-2 and are in different stages of clinical trials. In 2020, the US Food 
and Drug Administration (FDA) approved the emergency use of neutralizing mAbs for 
less severe SARS-CoV-2 cases in the USA [20]. Bamlanivimab has been approved to be 
used either alone or together with etesevimab, and casirivimab with imdevimab [20]. The 
emergence of new SARS-CoV-2 variants acts as a hurdle to mAb therapy as well as vaccine 
protection. Similar to the vaccines that target the S protein, some SARS-CoV-2 mutations 
can also resist neutralization by mAbs currently in clinical trials, to convalescent plasma 
and plasma from vaccinated individuals [22–39]. Table 1 shows mAbs that are in different 
stages of clinical trials and their effectiveness against different mutations. Therefore, to 
effectively treat the patients with mAbs and vaccinate high-risk populations, it becomes 
necessary to know the type of mutation(s)/variant(s) that these patients carry and that are 
in circulation, respectively. Mutations that aid SARS-CoV-2 in adaptation to the host are 
called adaptive mutations. Escape mutations, a subgroup of adaptive mutations, help the 
virus to slip past the host’s immune defenses. Some mutations only emerge/dominate 
during prolonged infections in immunocompromised patients (prolonged infections’ mu-
tations: long-term COVID-19 infections). 
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Table 1. List of adaptive and prolonged infections’ mutations in the RBD of the SARS-CoV-2 S protein studied and their 
resistance to mAbs that are in emergency use and clinical trials ⁑. 
Type Mutation Resistance to mAbs # (Fold Change Compared to SARS-CoV-2 Wuhan-Hu-1 Isolate) 
Adaptive 
R346K C135 (≥100-fold) PVH, PVV [37] 
K417N casirivimab (43-fold) PVM [40], (5.7-fold) PVH [36], (7-fold) PVV [32] 
K417T data not available 
N439K C135 (≥100-fold) PVH [37], (33.1-fold) PVV [37]; imdevimab (5-fold) PVV [41], (>100-fold) PVV [32] 
L452Q data not available 
L452R bamlanivimab (≥100-fold) PVV [32]; bamlanivimab/etesevimab (7.4-fold) PVV [32] 
Y453F casirivimab (≥100-fold) PVV [29,32], (>25.6-fold)PVV [41]; casirivimab/imdevimab (3.5-fold) PVV [29] 
S477N no resistance to current mAbs 
T478K no resistance to current mAbs 
T478R data not available 
E484K 
bamlanivimab (≥100-fold) PVV [31,32]; bamlanivimab/etesevimab (17-fold) PVV [32]; C135 (3.5-
fold) PVH [37]; C144 (≥100-fold) PVH, PVM [37,40]; casirivimab (20.2-fold) PVV [29], (55-fold) PVM [40], 
(4.4-fold) PVV [41], (25-fold) PVV [32]; casirivimab/imdevimab (4-fold) PVM [40]; etesevimab (4.4-
fold) PVV [31] 
E484Q 
bamlanivimab (≥100-fold) PVV [31,32]; bamlanivimab/etesevimab (22-fold) PVV [32]; C144 (≥100-
fold) PVH, PVV [37,42]; casirivimab (19-fold)P VV [32], (63.3-fold)PVH [43]; casirivimab/imdevimab 
(4.5-fold)PVH [43]  
F490S bamlanivimab (≥100-fold)PVV [31,32]; C144 (4.9-fold)PVH [37] 
S494P 
bamlanivimab (>100-fold)PVV [31], (>71-fold)PVV [32]; C144 (>100-fold)PVH [42], (60.8-fold)PVH [37], 
(17-fold)PVV [37]; casirivimab (5-fold)PVV [32] 





T415A data not available 
T470N data not available 
V483A bamlanivimab (48-fold)PVV [32] 
E484A C144 (≥100-fold)PVH, PVV [37,42] 
F486I data not available 
Q493K C144 (≥100-fold) PVH, PVV [37]; casirivimab (≥100-fold) PVV [29,32], (>25.6-fold) PVV [41] 
Q493R bamlanivimab (≥100-fold) 
PVV [32]; bamlanivimab/etesevimab (≥100-fold) PVV [32]; casirivimab 
(70-fold) PVV [32]; C144 (≥100-fold) PVH, PVV [37,42]; imdevimab (5-fold) PVV [32] 
⁑ Residue positions and resistance data were taken from Stanford University’s coronavirus antiviral and resistance data-
base (CoV-RDB) using the following link: https://covdb.stanford.edu/ (accessed on 29 May 2021) [45]. # Resistance ≤3.4-
fold is not shown here. PVH = pseudovirus (HIV), PVM = pseudovirus (MLV), PVV = pseudovirus (VSV). 
In the present study, using the available nucleotide sequence data on the NCBI 
COVID-19 database, we estimated the global prevalence of adaptive and prolonged infec-
tions’ mutations, in the receptor-binding domain (RBD) of the S protein, i.e., amino acid 
positions between 333 and 527. While similar prior studies exist [22,46], this study offers 
the latest update (along with CovMT) and uniquely focuses on the adaptive and pro-
longed infections’ mutations. Further, in this study, we have shown a simple way of han-
dling a large dataset (roughly 25 GB of sequence data) and acquiring the necessary data 
within a very short time without the need for massive computing power and advanced 
programming knowledge. During the last 2 months, a massive increase in the delta vari-
ant was reported in the human population (especially in the UK). Thus, we also compared 
the dynamics of both the adaptive and prolonged infections’ mutations in the global pop-
ulation by initially splitting the whole dataset into two timelines: end of 2019 till 29 May 
2021 and 30 May 2021 till 28 July 2021. Further, end of 2019 till 29 May 2021 dataset was 
split into six timelines and time course of the appearance of the mutations until 29 May 
2021 was studied. The data from this study can be used in conjuncture with the 
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coronavirus antiviral and resistance database (CoV-RDB) of Stanford University [45]. We 
found the prevalence of adaptive mutations in the global population to be quite signifi-
cant, especially the N501Y, L452R, T478K, E484K and S477N mutations. 
2. Materials and Methods 
A total of 984,769 SARS-CoV-2 nucleotide sequences was retrieved in FASTA format 
from the NCBI COVID-19 database (https://www.ncbi.nlm.nih.gov/sars-cov-2/) (accessed 
on 28 July 2021). Based on the release date, the dataset was split into two timelines: end of 
2019 till 29 May 2021, and 30 May 2021 till 28 July 2021. For convenience in data handling, 
the large FASTA files were further split into smaller files using the FASTA Splitter Perl 
script developed by Kirill Kryukov (http://kirill-kryukov.com/study/tools/fasta-splitter/) 
(accessed on 28 July 2021). Nucleotide sequences were aligned using the MAFFT v7 align-
ment program [47]. To do the alignment, a free web server provided by the Osaka Uni-
versity, Japan, was used (https://mafft.cbrc.jp/alignment/server/add_frag-
ments.html?frommanualnov6) (accessed on 28 July 2021). Alignment was performed with 
default parameters, except for ambiguous sequences, which were not removed during this 
alignment. SARS-CoV-2 isolate Wuhan-Hu-1 (NCBI accession number: NC_045512.2) was 
used as the reference for the alignment. The aligned sequences were then processed using 
AliView (https://ormbunkar.se/aliview/) (accessed on 28 July 2021) [48]. During this stage, 
sequences that did not contain the region of interest were removed. The nucleotide se-
quences were then translated into protein sequences using BioEdit v7.2.5, and the protein 
sequences were exported as an XML file [49]. Table 1 shows the specific mutations stud-
ied. These mutations were chosen based on information provided on Stanford Univer-
sity’s CoV-RDB (https://covdb.stanford.edu/page/mutation-viewer/) (accessed on 29 May 
2021). Some adaptive mutations, namely Y453F, S477N, T478K, E484K, S494P and N501Y, 
were also found in long-term COVID-19 infections. Unless stated differently, we consid-
ered these mutations as only adaptive. Mutations were counted semi-manually. In the 
case of countries having more than 50 sequences, Search+ written by Amar Ghosh 
(https://github.com/amarghosh/searchplus) (accessed on 28 July 2021), a plugin of Note-
pad++, was used. Compiled Search+ plugin (ready-to-use) for use with Notepad++ 32-bit 
is provided in the Supplementary Material. Specific tetrapeptide sequences were pro-
vided as the input for the search.  
3. Results and Discussion 
SARS-CoV-2 is rapidly evolving, and countries around the world are struggling to 
cope with new variants. On 31 May 2021, the WHO named these variants from alpha to 
kappa (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) (accessed on 
31 May 2021). These variants have been shown to exhibit reduced susceptibility to some 
of the mAbs that are under clinical trials, to convalescent plasma and plasma from vac-
cinated people [22–39]. Table 1 shows mutations and their level of resistance to mAbs that 
are in different stages of clinical trials currently. Further, pieces of evidence suggest that 
several of these mutations might reduce the effectiveness of some of the vaccines that are 
given to the public [19,50]. Knowing the prevalence of these mutations will aid in imple-
menting better vaccination strategies and better treatment for patients. Further, as the in-
fection is spread via infected humans to a healthy human, it will aid in postulating better 
control strategies. Understanding the importance of these mutations, several countries 
around the globe regularly sequenced the virus collected from their patients and depos-
ited sequence information in some of the public repositories. To this end, we have re-
trieved 984,769 SARS-CoV-2 nucleotide sequences from the NCBI database for this study. 
After alignment, nearly 1400 sequences were removed from further analysis, as these se-
quences lacked the region of interest. Figure 1A shows the residue positions (region of 
interest) and their corresponding mutation(s) that we studied. To reduce complexity and 
to make sense of the available mutation data, we considered only specific mutation(s) at 
specific residue positions, and even in this case, we did not study the prevalence of the 
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entire spectrum of amino acid substitutions at the studied residue positions. Further, we 
did not study the prevalence of mutations in combinations. The main reason for this is 
that variants are classified as alpha, beta, etc., based on the presence/absence of signature 
mutation(s), and not all members within a classification carry the same set of additional 
mutations. Moreover, as new mutations arise in the human population at regular inter-
vals, the way we infer resistance might change. Thus, we studied stand-alone mutations 
that have a significant effect on treatment with mAbs. Figure 1B shows the conti-
nent/country-wise distribution of the studied SARS-CoV-2 sequences (timeline: end of 
2019 till 29 May 2021). From the figure, it can be seen that a major proportion of these 
sequences come from Switzerland (3.5%), the UK (34.2%) and the USA (57.4%). This is not 
surprising, as countries with good economies understood the severity of the threat this 
virus holds and have invested significant resources in sequencing patient samples and 
became frontrunners in tracking these variants. A report from the Wall Street Journal on 30 
Jan 2021 stated that the UK became the world leader in sequencing the coronavirus ge-
nome as they alerted the world about the identification of the alpha variant, while other 
countries are lagging (report by Joanna Sugden). Because of this, the prevalence data 
shown here might also be biased. This could be avoided in the future if more countries 
around the world come forward in sequencing their patient samples. 
 
Figure 1. Global prevalence of adaptive and prolonged infections’ mutations in the receptor-binding domain (RBD) of the 
SARS-CoV-2 spike (S) protein until 29 May 2021. (A) SARS-CoV-2 virion (left) and schematics of the S protein (right). The 
S protein consists of two subunits, namely S1 and S2. The S1 subunit comprises of N-terminal domain (NTD) and receptor-
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binding domain (RBD). The receptor-binding motif (RBM) is the region within RBD that binds to the angiotensin-convert-
ing enzyme 2 (ACE2) receptor. Numbers in black indicate the residue index of the S protein in the SARS-CoV-2 reference 
genome (NCBI accession number: NC_045512.2). ROI = region of interest. Adaptive mutations are represented in red, 
while prolonged infections’ mutations are represented in blue. (B) Bar graph showing the continent/country-wise distri-
bution of SARS-CoV-2 sequences. For the percentage calculation, the total number of sequences (n = 524,124) was used. € 
= Europe without Switzerland and the UK. ‡ = North America without the USA. (C) Bar graph showing the percentages 
(%) of the respective adaptive mutations. (D) Bar graph showing the percentages (%) of the respective prolonged infec-
tions’ mutations. 
3.1. Prevalence of Adaptive Mutations until 29 May 2021 
We studied the prevalence of 15 specific adaptive mutations, and the information 
regarding these mutations was retrieved from the Stanford corona antiviral and resistance 
database (CoV-RDB) [45]. Irrespective of continents/countries, the prevalence of these 
adaptive mutations until 29 May 2021 was found to have the following order in the global 
population; N501Y (41.24%) > L452R (6.75%) > E484K (5.32%) > S477N (4.74%) > K417T 
(1.82%) > T478K (1.8%) > S494P (1.11%), while the rest of the mutations were found in less 
than 0.7% of the sequences, with Y453F being the least found (0.01%) (Figure 1C). The 
Y453F mutation was originally identified in SARS-CoV-2 isolated from minks in Denmark 
[51]. Although this mutation increases the binding affinity with the ACE2 receptor, the 
prevalence of this mutation was found to be low in the global human population with the 
highest prevalence in Denmark (8/14 sequences) [51,52]. Our study also corroborates ear-
lier data. Continent/country-wise prevalence data of adaptive mutations (in %) are pro-
vided in Table 2. Raw data for country-wise prevalence are provided in the Supplemen-
tary Materials. The K417N/T mutation has been shown to have impaired ACE2 binding 
[35,53]. The K417N mutation was first identified in South Africa (beta variant), while the 
K417T mutation was first identified in Brazil (gamma variant) [54,55]. In our study, the 
highest prevalence of the K417N mutation was found in Finland (2/13 sequences), fol-
lowed by the Philippines (8/71 sequences). On the other hand, the highest prevalence of 
the K417T mutation was found in Uruguay (1/10 sequences) followed by Brazil (2/27 se-
quences). In the case of the N439K mutation, studies have shown enhanced binding to the 
ACE2 receptor [24,56,57]. This mutation has the highest prevalence in Estonia (3/12 se-
quences) followed by Austria (25/124 sequences). The L452R mutation was first identified 
in California, USA (epsilon variant) [58], and as a double mutant with the E484Q mutation 
in sequences isolated from Maharashtra, India (kappa variant) (BBC News published on 
25 March 2021), and also as a double mutant with the T478K mutation in sequences iso-
lated from India (delta variant). In our study, the highest prevalence of L452R was found 
in Nepal (8/11 sequences), followed by Romania (1/2 sequences). In the UK, the prevalence 
of this mutation was found in less than 0.07% of the sequences, while in the USA, the 
prevalence was found to be 11.56%. Like the N439K mutation, the S477N mutation has 
been shown to exhibit enhanced ACE2 receptor binding [56]. The highest prevalence of 
this mutation was found in sequences from Australia (10087/13298 sequences), followed 
by sequences from Hungary (10/36 sequences). The T478K mutation, which is one of the 
signature mutations in the Indian variant (delta variant), was first identified in sequences 
isolated from Mexico and California, USA (B.1.1.519 lineage) [59]. In our study, the highest 
prevalence of the T478K mutation was in sequences from Nepal (7/11 sequences) followed 
by Morocco (1/14 sequences). The T478R mutation was originally isolated from travelers 
who travelled within countries in southern Africa [60]. However, in our study, the T478R 
mutation was identified only in two countries, namely the USA (119/300280 sequences) 
and the UK (12/178878 sequences). E484K is one of the prime RBM mutations found in 
many SARS-CoV-2 variants, namely alpha (UK), beta (South Africa), gamma (Brazil), 
theta (Philippines) and iota (New York, USA) [53–55,61–66]. Mutations at E484 reduce the 
binding and neutralization by RBD targeting polyclonal plasma antibodies significantly 
(>10-fold) [34]. The E484Q mutation, on the other hand, was identified along with the 
L452R mutation in the kappa variant. The E484K mutation was highly prevalent in Libya 
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(28/34 sequences), followed by South Africa (2/3 sequences), while the E484Q mutation 
was highly prevalent in Nepal (1/11 sequences) followed by Bahrain (12/269 sequences). 
The F490S mutation was earlier identified in a few sequences isolated in Peru and Chile 
[67]. This mutation was found to be highly prevalent in sequences isolated from Peru 
(26/127 sequences) followed by sequences isolated from the West Bank (6/62 sequences). 
The S494P mutation was earlier identified in sequences isolated from Santa Cruz County, 
USA [68]. This mutation has been predicted to have enhanced binding with the ACE2 
receptor [69] and was highly prevalent in sequences isolated from Russia (31/304 se-
quences), followed by sequences isolated from the USA (5167/300280 sequences). Finally, 
N501Y is another prime RBM mutation found in many SARS-CoV-2 variants, namely al-
pha, beta, gamma and theta [54,55,65,70,71]. This mutation has been shown to increase the 
ACE2 binding and enhances the viral replication in the upper respiratory tract [56,72–75]. 
More than half of the sequences isolated in the UK until 29 May 2021 were found to carry 
this mutation, while around 40% of the sequences isolated in the USA during the same 
period were found to carry this mutation. This mutation was found in greater proportions 
in sequences isolated from nearly 41 countries. Some of the adaptive mutations that we 
have studied here have been shown by others to have a moderate to a very high level of 
resistance (≥100-fold) towards some of the mAbs that are currently either in emergency 
use in patients or different stages of clinical trials, to convalescent plasma and plasma 
from vaccinated individuals (Table 1) [22–39]. 
Table 2. Continent/country-wise prevalence of adaptive mutations in the receptor-binding domain of the SARS-CoV-2 







R346K K417N K417T N439K L452Q L452R Y453F S477N T478K T478R E484K E484Q F490S S494P N501Y 
Africa 1728  0.347  0.289  5.845 0.058 1.678 0.058  4.456 0.174  0.058 9.028 
Asia 3703 0.135 1.242 0.351 0.270 0.027 1.836  0.513 1.053  1.782 0.702 0.189  7.399 
Europe € 6092 0.033 0.509 0.312 1.346  0.575 0.230 5.368 0.066  1.625 0.033  0.657 26.133 
Switzerland 18,234 0.362 0.516 0.126 4.442 0.005 1.475 0.016 21.213 0.801  0.856 0.038 0.033 0.104 17.906 
UK 178,878 0.003 0.084 0.004 1.348 0.002 0.070 0.004 1.094 0.010 0.007 0.214 0.013 0.051 0.323 51.055 
North Amer-
ica ‡ 
99        2.020   9.091    1.010 
USA 300,280 0.041 0.424 3.147 0.034 0.119 11.556 0.010 2.836 3.067 0.040 9.005 0.089 0.162 1.721 39.631 
Oceania 13,299        75.848      0.008 0.278 
South America 603   0.663  4.312      1.990  4.312  0.995 
€ = Europe excluding Switzerland and the UK; ‡ = North America excluding the USA; empty cell = 4 or more decimal places 
or 0%. 
3.2. Prevalence of Prolonged Infections’ Mutations until 29 May 2021 
We studied the prevalence of seven specific prolonged infections’ mutations (Table 
3). Globally, these mutations were less prevalent in the studied sequences with the V483A 
mutation having the highest prevalence (0.014%) (Figure 1D). Table 3 shows the conti-
nent/country-wise prevalence of prolonged infections’ mutations (in %) in the receptor-
binding domain of the SARS-CoV-2 spike protein. Country-wise, V483A mutation was 
found only in the USA (63/300280 sequences) and the UK (11/178878 sequences). World-
wide, except for the V483A mutation, other mutations were found in <0.008% of the se-
quences: Q493R (0.007%) >Q493K (0.006%) >T415A (0.005%) >E484A (0.002%) >T470N 
(0.001%) (Figure 1D). The T415A mutation was found only in sequences from three coun-
tries, namely Italy (2/258 sequences), the USA (21/300280 sequences) and the UK (2/178878 
sequences). Similar to the V483A mutation, the T470N mutation was also found only in 
sequences from the USA (4/300280 sequences) and the UK (2/178878 sequences). The 
E484A mutation was identified only in sequences from Hong Kong (1/339 sequences), the 
UK (3/178878 sequences) and the USA (4/300280 sequences). The F486I mutation was not 
found in any of the studied sequences. The Q493K mutation was identified in sequences 
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from four countries, with the highest prevalence in Spain (1/1173 sequences) followed by 
the UK (13/178878 sequences), Switzerland (1/18234 sequences) and the USA (14/300280 
sequences), while the Q493R mutation was identified in sequences from three countries 
with the highest prevalence in Italy (1/258 sequences) followed by the USA (25/300280 
sequences) and the UK (11/178878 sequences). Some of these mutations were either pre-
dicted and/or tested to have resistance towards bamlanivimab and etesevimab [76]. The 
V483A mutation was shown to resist bamlanivimab roughly 48-fold [32], while the E484A 
mutation was shown to resist C144 mAb greater than 100-fold [37]. Q493K/R mutations, 
although rare, were found to confer a very high resistance towards bamlanivimab [32], 
etesevimab [32], casirivimab [23,29,33], C121 [37] and C144 [37]. 
Table 3. Continent/country-wise prevalence of prolonged infections’ mutations in the receptor-binding domain of the 
SARS-CoV-2 spike protein until 29 May 2021. 
Continent/Country No. of Studied 
Sequences 
Mutation (%) 
T415A T470N V483A E484A F486I Q493K Q493R 
Africa 1728        
Asia 3703    0.027    
Europe € 6092 0.033     0.016 0.016 
Switzerland 18,234      0.005  
UK 178,878 0.001 0.001 0.006 0.002  0.007 0.006 
North America ‡ 99        
USA 300,280 0.007 0.001 0.021 0.001  0.005 0.008 
Oceania 13,299        
South America 603        
€ = Europe excluding Switzerland and the UK; ‡ = North America excluding the USA; empty cell = 4 or more decimal places 
or 0%. 
3.3. Prevalence of Adaptive Mutations from 30 May 2021 till 28 July 2021 
From 30 May 2021 till 28 July 2021, 460,645 SARS-CoV-2 nucleotide sequences were 
released in the NCBI database. Of these sequences, 177 sequences were removed from 
further analysis due to the lack of the region of interest/poor sequence quality. In this 
dataset, sequences from Germany, Switzerland, the UK and USA constituted about 98% 
of the total sequences (Figure 2A). Irrespective of continents/countries, the prevalence of 
these adaptive mutations between 30 May 2021 and 28 July 2021 were found to have the 
following order in the global population: N501Y (56.61%) > L452R (29.8%) > T478K 
(28.54%) > E484K (3.97%) > S477N (1.65%) > K417T (1.45%). The rest of the mutations were 
found in less than 0.8% of the sequences with Y453F being the least found (0.004%) (Figure 
2B). During this period, N501Y, L452R and T478K mutations increased by 15.39, 23.06 and 
26.75% points, respectively, while E484K, S477N, K417T and S494P mutations decreased 
by 1.35, 3.09, 0.37 and 0.88% points, respectively. As mentioned earlier, L452R and T478K 
are signature mutations in the delta variant. Our data confirm that the prevalence of the 
delta variant has increased considerably in the last two months in the global population. 
On the continent/country-level, the highest prevalence of the L452R mutation was ob-
served in Asia (57.90%), followed by the UK (49.1%) and the USA (23.34%) (Table 4), and 
the highest prevalence of the T478K mutation was again observed in Asia (50.59%) fol-
lowed by the UK (48.63%) and the USA (18.64%) (Table 4). Comparing the two timelines, 
the prevalence of L452R increased by roughly 56.07, 49.01 and 11.78% points in Asia, the 
UK and USA, respectively. Similarly, the prevalence of T478K increased roughly by 49.54, 
48.62 and 15.57% points in Asia, the UK and USA, respectively. These data indirectly show 
that the prevalence of the delta variant in the UK has increased tremendously in the last 
two months. Within Asia, the highest prevalence of the L452R mutation was observed in 
Uzbekistan (92%) followed by India (75.65%), Bahrain (73.03%) and Myanmar (71.43%) 
(Supplementary Material). Similarly, the highest prevalence of the T478K mutation was 
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observed in Uzbekistan (76%), followed by Bahrain (73.03%), India (61.36%) and Bangla-
desh (44.33%) (Supplementary Material). As mentioned before, E484K is one of the prime 
RBM mutations found in several SARS-CoV-2 variants, and mutations at E484 reduce the 
binding and neutralization by RBD targeting polyclonal plasma antibodies significantly 
(>10-fold) [34]. Though a reduction in the prevalence of E484K was observed globally, the 
prevalence of this mutation has increased by 2.09, 1.06, 0.45 and 5.13% points in Germany, 
Switzerland, the UK and USA, respectively, in the last 2 months (Figures 1 and 2). 
 
Figure 2. Global prevalence of adaptive and prolonged infections’ mutations in the receptor-binding domain (RBD) of the 
SARS-CoV-2 spike (S) protein from 30 May 2021 till 28 July 2021. (A) Bar graph showing the continent/country-wise dis-
tribution of SARS-CoV-2 sequences. For the percentage calculation, the total number of sequences (n = 460,645) was used. 
§ = Europe without Germany, Switzerland and the UK. ‡ = North America without the USA. (B) Bar graph showing the 
percentages (%) of the respective adaptive mutations. (C) Bar graph showing the percentages (%) of the respective pro-
longed infections’ mutations. 
Table 4. Continent/country-wise prevalence of adaptive mutations in the receptor-binding domain of the SARS-CoV-2 







R346K K417N K417T N439K L452Q L452R Y453F S477N T478K T478R E484K E484Q F490S S494P N501Y 
Africa 271  11.808    11.439   1.107  20.664 0.369 0.738 3.321 49.815 
Asia 1354  7.090 0.148 0.074  57.903  0.148 50.591 0.074 6.499 6.721 0.074  23.560 
Europe § 7400 0.014 0.311 0.041 3.608 0.027 0.122  1.041 0.027  0.554 0.014 0.041 0.027 17.270 
Germany 120,429 0.033 1.476 0.453 2.148 0.121 3.310 0.002 2.352 2.819 0.011 3.582 0.134 0.542 0.174 79.022 
Switzerland 17,578 0.233 0.688 0.484 2.463 0.017 2.890  9.148 2.020 0.006 1.911 0.091 0.307 0.165 58.095 
UK 229,321 0.007 0.256 0.065 0.090 0.003 49.075  0.025 48.633  0.666 0.171 0.112 0.054 48.698 
North Amer-
ica ‡ 
66      3.030   1.515  6.061    1.515 
USA 83,122 0.066 0.929 6.950 0.011 0.217 23.336 0.018 3.621 18.640 0.017 14.132 0.109 0.393 0.829 50.363 
Oceania 634        0.946        





293   37.201 0.341 1.024      62.457  1.024 0.341 39.249 
§ = Europe excluding Germany, Switzerland and the UK; ‡ = North America excluding the USA; empty cell = 4 or more 
decimal places or 0%. Prevalence of prolonged infections’ mutations from 30 May 2021 till 28 July 2021. 
3.4. Prevalence of Prolonged Infections’ Mutations from 30 May 2021 till 28 July 2021 
Similar to the previous timeline, globally, these mutations were less prevalent. How-
ever, unlike the previous timeline, during this period, Q493R (0.011%) was found to be 
the dominant mutation followed by Q493K (0.007%), E484A (0.005%), V483A (0.004%), 
T470N (0.002%), T415A and F486I (Figure 2C). During this period, the prevalence of 
Q493R, Q493K, E484A and T470N increased by 0.004, 0.001, 0.003 and 0.001% points, re-
spectively, while the prevalence of V483A and T415A decreased by 0.01 and 0.005% 
points, respectively. As mentioned before, the Q493R mutation alone confers significant 
resistance towards bamlanivimab, etesevimab, casirivimab and C144 [32,37,42]. On the 
continent/country level, this mutation was found in only sequences from three countries: 
the USA (24/83122 sequences), the UK (23/229321 sequences) and Germany (4/120429 se-
quences) (Table 5). Q493K and E484A mutations were found in only sequences from Swit-
zerland, the UK, USA and Germany. Of these four countries, both these mutations were 
found to be highly prevalent in sequences isolated from Switzerland (Table 5). Unlike the 
previous timeline, V483A was additionally identified in sequences from Egypt and Ger-
many. It is worth noting that 3 out of 65 sequences from Egypt carried this mutation (Sup-
plementary Material). Until 29 May 2021, the T470N mutation was identified only in se-
quences from the UK and USA. During the last two months, this mutation was confined 
within Europe, especially in Estonia, Germany, Switzerland and the UK. In Estonia, 5 out 
of 1635 sequences carried this mutation (Supplementary Material). During the same pe-
riod, on the other hand, the T415A mutation was confined within the USA (Table 5), and 
the prevalence almost doubled. Finally, until 29 May 2021, the F486I mutation was not 
identified in any of the sequences. Between 30 May 2021 and 28 July 2021, this mutation 
was identified in one of the 83,122 studied sequences from the USA. 
Table 5. Continent/country-wise prevalence of prolonged infections’ mutations in the receptor-binding domain of the 
SARS-CoV-2 spike protein from 30 May 2021 till 28 July 2021. 
Continent/ 
Country 
No. of Studied 
Sequences 
Mutation (%) 
T415A T470N V483A E484A F486I Q493K Q493R 
Africa 271   1.107     
Asia 1354        
Europe § 7400  0.068      
Germany 120,429  0.001 0.004 0.002  0.002 0.003 
Switzerland 17,578  0.006  0.057  0.011  
UK 229,321  0.002 0.001 0.003  0.010 0.010 
North America ‡ 66        
USA 83,122 0.002  0.010 0.006 0.001 0.006 0.029 
Oceania 634        
South America 293        
§ = Europe excluding Germany, Switzerland and the UK; ‡ = North America excluding the USA; empty cell = 4 or more 
decimal places or 0%. 
3.5. Time Course of the Appearance of the Mutations until 29 May 2021 
To study the time course of the appearance of the mutations, we split the data into 
six timelines, with each timeline covering about 3 months except the last timeline, which 
covered approximately 4 months: Timeline 1 (1 November 2019 till 31 January 2020: T1), 
Timeline 2 (1 February 2020 till 30 April 2020: T2), Timeline 3 (1 May 2020 till 31 July 2020: 
T3), Timeline 4 (1 August 2020 till 31 October 2020: T4), Timeline 5 (1 November 2020 till 
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31 January 2021: T5) and Timeline 6 (1 February 2021 till 29 May 2021: T6). T1, T2, T3, T4, 
T5 and T6 had the following respective sequence distributions: 0.006%, 0.32%, 2.07%, 
4.68%, 3.81% and 90.13%. This shows that a similar number of SARS-CoV-2 sequences 
were released by the NCBI from 1 February 2021 to 29 May 2021 and from 30 May 2021 to 
28 July 2021. In T1, none of the sequences carried any adaptive and prolonged infections’ 
mutations. In T2, nearly 0.76% of sequences from the USA carried the V483A mutation. 
Country-wise raw data on the prevalence of SARS-CoV-2 receptor-binding domain (RBD) 
mutations concerning different timelines is provided in the Supplementary Material. No 
other mutation was observed in T2. In T3, mutations N439K, Y453F, S477N, V483A, 
E484K, E484Q, S494P and N501Y were observed. While N439K, Y453F, V483A, E484K, 
S494P and N501Y mutations were only observed in sequences from the USA (0.015%), 
Netherlands (33.33%), USA (0.21%), USA (0.01%), USA (0.04%) and Australia (0.99%), re-
spectively, S477N and E484Q were identified in more than one country with the highest 
prevalence in Lebanon (25%) and India (0.44%), respectively. In T4, apart from the muta-
tions identified in T3, mutations R346K, L452Q, L452R and T478K were observed. While 
R346K and L452R mutations were observed only in sequences from Iraq with a prevalence 
of 7.41% and 1.85%, respectively, the other two mutations were observed only in se-
quences from the USA, with each having a prevalence of approximately 0.009%. In T5, 
except for the L452Q mutation, all other mutations discussed above were observed. Ad-
ditionally, mutations K417N, K417T, T470N, T478R, E484A, F490S and Q493K were ob-
served. All these mutations were observed only in sequences from the USA except for the 
K417T mutation, which was also found in a sequence from Italy. The prevalences of these 
mutations were quite low (≤0.04%). Finally, mutations T415A and Q493R were observed 
in T6 apart from the other mutations discussed above. Both these mutations were identi-
fied only in sequences from the USA, UK and Italy. It is worth noting that both these 
mutations were found to be highly prevalent in sequences from Italy compared to those 
from the USA and UK. 
In conclusion, globally, we found a high prevalence of N501Y mutation in the RBD 
of the SARS-CoV-2 S protein using the available sequence data from the NCBI database 
up to 28 July 2021. Further, we observed a considerable prevalence of other adaptive mu-
tations in the RBD, namely L452R, T478K, E484K, S477N, K417T, N439K and S494P. Pro-
longed infections’ mutations were observed only in a few sequences from a few countries. 
A few drawbacks in our study, like any other epidemiological study, are the available 
number of sequences from each country, the context to which the sequencing was done in 
the first place, etc. Because of these reasons, the data presented here might be skewed and 
should be used with caution. Further, we did not use the sequences from the GISAID 
(https://www.gisaid.org/) (accessed on 3 August 2021) database, which contained 
2,568,717 sequences at the time of writing this manuscript, as one needs prior permission 
to use the data. Thus, we used only sequences from the NCBI database as they are readily 
accessible by anyone without any registration and/or signing any agreement. Moreover, 
the GISAID database has inbuilt visualization software using which variants (mutations) 
can be analyzed. In addition, many online visualization tools (e.g., CovMT) use data from 
the GISAID database. To our knowledge, no such tools use sequence data deposited in 
the NCBI database. To analyze large sequence data, in many cases, specialized computa-
tional skills/hardware requirements are needed. This motivated us to use the data from 
the NCBI database and develop a methodology. It should be noted that not all SARS-CoV-
2 sequences are deposited in the NCBI and GISAID databases. Anyone interested in stud-
ying the prevalence of mutations (variants of concern, variants of interest and variants 
under monitoring) from sequences isolated locally or regionally can follow our method-
ology, and our methodology is not limited only to the SARS-CoV-2 sequences. Like the 
UK, USA, Germany and Switzerland, many countries should actively sequence as many 
SARS-CoV-2 sequences as possible from patients and deposit them in the public reposi-
tory. This will aid in a better understanding of the viral evolution in the human popula-
tion. As more sequence information gets deposited in the public database regularly, we 
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might/will observe a change in the prevalence landscape shortly, as we have observed for 
the delta variant. Thus, it is necessary to do this type of study at regular intervals to keep 
ourselves updated about the latest dominant mutation(s), both globally and regionally (or 
locally), and thereby we can evolve our control strategies and put a full stop to the spread 
of this devastating viral infection. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/v13101974/s1, Country-wise raw data on the prevalence of SARS-CoV-2 receptor-bind-
ing domain (RBD) mutations: 2019 till 29 May 2021, 30 May 2021 till 28 July 2021 and different time 
lines (T1–T6) are provided as Excel files. Compiled Search+ plugin (ready-to-use) for use with Note-
pad++ 32-bit is also provided. 
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